Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T15482 |
HIF-2α-IN-1
|
HIF | Angiogenesis; Chromatin/Epigenetic |
HIF-2α-IN-1是一种有效的 HIF-2α 抑制剂, IC50值小于500 nM。 | |||
T61349 |
HIF-1α-IN-2
|
HIF | Angiogenesis; Chromatin/Epigenetic |
HIF-1α-IN-2 是一种新型高效的 HIF-1α 抑制剂,具有抗癌抗肿瘤活性,以剂量依赖的方式抑制 HIF-1α 和 VEGF 的表达,抑制细胞迁移。 | |||
T61442 | HIF-1/2α-IN-1 | ||
HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α. Its inhibitory effect on HIF-2α activity is significant, with an IC 50 value of 0.92 μM. Furthermore, HIF-1/2α-IN-1 has the ability to decrease HIF-1α levels. This compound is particularly valuable for research on clear cell renal cell carcinoma (ccRCC) [1]. | |||
T61102 |
HIF-1/2α-IN-2
|
||
HIF-1/2α-IN-2 is a potent inhibitor of HIF-1/2α, which effectively reduces the levels of HIF-1/2α. This compound elicits an iron starvation response by specifically targeting ISCA2, a key protein involved in Iron Sulfur Cluster Assembly 2. [1] | |||
T78123 |
HIF-1α-IN-2 hydrochloride
|
HIF/HIF Prolyl-Hydroxylase | Chromatin/Epigenetic; Metabolism |
HIF-1α-IN-2 hydrochloride 是一款有效的 HIF-1α 抑制剂,对抗癌活性显著,其在MDA-MB-231细胞和MiaPaCa-2细胞中的IC50值分别为28 nM和15 nM。该化合物主要通过抑制转录和阻碍蛋白质合成来下调HIF-1α的表达。 | |||
T61367 |
HIF-2α-IN-6
|
||
HIF-2α-IN-6 (117) 是HIF-2α的抑制剂。 | |||
T61614 |
HIF-2α-IN-5
|
||
HIF-2α-IN-5 是一种有效的 HIF-2α的抑制剂,IC50小于 50 nM。 | |||
T72997 |
HIF-2α-IN-7
|
||
HIF-2α-IN-7 是一种缺氧诱导因子 2α(HIF-2α)抑制剂。HIF-2α-IN-7 抑制 HIF-2α,EC50值为 6 nM。HIF-2α-IN-7 可用于多种疾病的研究,包括癌症、肝病、炎性疾病、肺病和铁负荷紊乱。 | |||
TP2046L |
TAT-cyclo-CLLFVY acetate(1446322-66-2 Free base)
|
||
TAT-cyclo-CLLFVY acetate(1446322-66-2 Free base) 是一种选择性 HIF-1 二聚化抑制剂。 TAT-cyclo-CLLFVY acetate 阻断重组 HIF-1α 与 HIF-1β 的蛋白质-蛋白质相互作用,但不阻断 HIF-2α 与 HIF-1β (IC50 = 1.3 μM)。 TAT-cyclo-CLLFVY acetate 在体外抑制缺氧诱导的 HIF-1 活性,并降低骨肉瘤和乳腺癌细胞中 VEGF 和 CAIX 的表达。 TAT-cyclo-CLLFVY acetate 减少缺氧 HUVEC 的管状化。 | |||
T78937 |
HIF-2α-IN-9
|
HIF/HIF Prolyl-Hydroxylase | Chromatin/Epigenetic; Metabolism |
HIF-2α-IN-9(compound 35r)为HIF-2α抑制剂,能够抑制VEGF-A(IC50=305 nM),影响肿瘤细胞生长基因表达并促进巨噬细胞介导的肿瘤免疫反应。 | |||
TP2046 |
TAT-cyclo-CLLFVY
|
||
Selective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM). Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cance | |||
T36492 | CMC2.24 | ||
CMC2.24 (TRB-N0224) is an orally active tricarbonylmethane agent that demonstrates effectiveness in inhibiting Ras activation and the downstream effector ERK1/2 pathway, thus effectively combating pancreatic tumor formation in mice. Additionally, CMC2.24 exerts potent inhibitory effects on zinc-dependent MMPs, with IC50s ranging from 2.0-69 μM. Furthermore, CMC2.24 aids in alleviating the progression of osteoarthritis by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis throug... |